Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application

被引:115
|
作者
Reinisch, Andreas
Bartmann, Christina
Rohde, Eva
Schallmoser, Katharina
Bjelic-Radisic, Vesna
Lanzer, Gerhard
Linkesch, Werner
Strunk, Dirk
机构
[1] Med Univ, Dept Internal Med, Div Hematol & Stem Cell Transplantat, A-8036 Graz, Austria
[2] Med Univ, Dept Blood Grp Serol & Transfus Med, Graz, Austria
[3] Med Univ, Dept Obstet & Gynaecol, Graz, Austria
关键词
cord blood; good manufacturing practice; mesenchymal stromal cell; transplantation; umbilical cord blood;
D O I
10.2217/17460751.2.4.371
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background: Umbilical cord blood (UCB) is an easily accessible alternative source for multipotent mesenchymal stromal cells (MSCs) and is generally believed to provide MSCs with a higher proliferative potential compared with adult bone marrow. Limitations in cell number and strict dependence of expansion procedures from selected lots of fetal bovine serum have hampered the progress of clinical applications with UCB-derived MSCs. Methods: We analyzed the isolation and proliferative potential of human UCB MSCs compared with bone marrow MSCs under optimized ex vivo culture conditions. We further investigated human platelet lysate as an alternative to replace fetal bovine serum for clinical-scale MSC expansion. Clonogenicity was determined in colony-forming units-fibroblast assays. MSC functions were tested in hematopoiesis support, vascular-like network formation and immune modulation potency assays. Results: MSCs could be propagated from UCB with and without fetal bovine serum. MSC propagation was effective in 46% of UCB samples. Once established, the proliferation kinetics of UCB MSCs did not differ significantly from that of bone marrow MSCs under optimized culture conditions, resulting in more than 50 population doublings after 15 weeks. A clinical quantity of 100 million MSCs with retained differentiation potential could be obtained from UCB MSCs within approximately 7 weeks. Ex vivo expansion of hematopoietic UCB-derived CD34(+) cells as well as immune inhibition and vascular-like network formation could be shown for UCB MSCs propagated under both culture conditions. Conclusion: We demonstrate for the first time that human MSCs can be obtained and propagated to a clinical quantity from UCB in a completely bovine serum-free system. Surprisingly, our data argue against a generally superior proliferative potential of UCB MSCs. Functional data indicate the applicability of clinical-grade UCB MSCs propagated with human platelet lysate-conditioned medium for hematopoiesis support, immune regulation and vascular regeneration.
引用
收藏
页码:371 / 382
页数:12
相关论文
共 50 条
  • [31] UC blood-derived mesenchyrnal stromal cells: an overview
    Flynn, A.
    Barry, F.
    O'Brien, T.
    CYTOTHERAPY, 2007, 9 (08) : 717 - 726
  • [32] Influence of the mesenchymal stromal cell source on the hematopoietic supportive capacity of umbilical cord blood-derived CD34+-enriched cells
    Sara Bucar
    André Dargen de Matos Branco
    Márcia F. Mata
    João Coutinho Milhano
    Íris Caramalho
    Joaquim M. S. Cabral
    Ana Fernandes-Platzgummer
    Cláudia L. da Silva
    Stem Cell Research & Therapy, 12
  • [33] Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase la Clinical Trial
    Park, Eun Hye
    Lim, Hee-Suk
    Lee, Seunghee
    Roh, Kyounghwan
    Seo, Kwang-Won
    Kang, Kyung-Sun
    Shin, Kichul
    STEM CELLS TRANSLATIONAL MEDICINE, 2018, 7 (09) : 636 - 642
  • [34] Influence of the mesenchymal stromal cell source on the hematopoietic supportive capacity of umbilical cord blood-derived CD34+-enriched cells
    Bucar, Sara
    Branco, Andre Dargen de Matos
    Mata, Marcia F.
    Milhano, Joao Coutinho
    Caramalho, Iris
    Cabral, Joaquim M. S.
    Fernandes-Platzgummer, Ana
    da Silva, Claudia L.
    STEM CELL RESEARCH & THERAPY, 2021, 12 (01)
  • [35] Direct intracardiac injection of umbilical cord-derived stromal cells and umbilical cord blood-derived endothelial cells for the treatment of ischemic cardiomyopathy
    Suss, Paula H.
    Capriglione, Luiz Guilherme A.
    Barchiki, Fabiane
    Miyague, Lye
    Jackowski, Danielle
    Fracaro, Leticia
    Schittini, Andressa V.
    Senegaglia, Alexandra C.
    Rebelatto, Carmen L. K.
    Olandoski, Marcia
    Correa, Alejandro
    Brofman, Paulo R. S.
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2015, 240 (07) : 969 - 978
  • [36] Osteogenic differentiation of equine cord blood multipotent mesenchymal stromal cells within coralline hydroxyapatite scaffolds in vitro
    Figueroa, R. J.
    Koch, T. G.
    Betts, D. H.
    VETERINARY AND COMPARATIVE ORTHOPAEDICS AND TRAUMATOLOGY, 2011, 24 (05) : 354 - 362
  • [37] The significant cardiomyogenic potential of human umbilical cord blood-derived mesenchymal stem cells in vitro
    Nishiyama, Nobuhiro
    Miyoshi, Shunichiro
    Hida, Naoko
    Uyama, Taro
    Okamoto, Kazuma
    Ikegami, Yukinori
    Miyado, Kenji
    Segawa, Kaoru
    Terai, Masanori
    Sakamoto, Michiie
    Ogawa, Satoshi
    Umezawa, Akihiro
    STEM CELLS, 2007, 25 (08) : 2017 - 2024
  • [38] Distinct Differentiation Potential of "MSC" Derived from Cord Blood and Umbilical Cord: Are Cord-Derived Cells True Mesenchymal Stromal Cells?
    Bosch, Julia
    Houben, Amelie Pia
    Radke, Teja Falk
    Stapelkamp, Daniela
    Buenemann, Erich
    Balan, Percy
    Buchheiser, Anja
    Liedtke, Stefanie
    Koegler, Gesine
    STEM CELLS AND DEVELOPMENT, 2012, 21 (11) : 1977 - 1988
  • [39] Umbilical cord blood-derived cells for tissue repair
    Körbling, M
    Robinson, S
    Estrov, Z
    Champlin, R
    Shpall, E
    CYTOTHERAPY, 2005, 7 (03) : 258 - 261
  • [40] Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation
    Plantinga, Maud
    Lo Presti, Vania
    de Haar, Colin G.
    Dunnebach, Ester
    Madrigal, Alejandro
    Lindemans, Caroline A.
    Boelens, Jaap Jan
    Nierkens, Stefan
    FRONTIERS IN IMMUNOLOGY, 2020, 11